CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), a leading RNAi therapeutics company, today announced that it will host a conference call to discuss the full results from the Phase II GEMINI study of ALN-RSV01, being presented at the International Symposium on Respiratory Viral Infections in Singapore. The webcast will take place on Friday, February 29, 2008 at 8:30 a.m. ET.
